Playing the Waiting Game with GMP Guideline Revisions: Delays in revisions to guidelines by the European Union are impeding the pharmaceutical industry.

The article discusses the impact of delay in adaptation of European Union(EU) guidelines for good manufacturing practice (GMP) on the investment decisions of pharmaceutical industry. Topics include incorporation of key sections of the GMP guide including good distribution practice (GDP), comments of European Medicines Agency (EMA) on behalf of trade associations and professional association concerning guidelines, and enforcement of EMA for moving its headquarters from London to Amsterdam.